These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36604466)

  • 21. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.
    Sunavala-Dossabhoy G; Petti S
    Oral Oncol; 2023 Jan; 136():106280. PubMed ID: 36525783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
    Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
    Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
    Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
    Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
    Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
    Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
    Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving.
    Lodemann E; Bockisch A; Görges R
    Psychoneuroendocrinology; 2012 Oct; 37(10):1726-35. PubMed ID: 22541716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
    Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
    Liepe K
    Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials.
    Pak K; Cheon GJ; Kang KW; Kim SJ; Kim IJ; Kim EE; Lee DS; Chung JK
    J Korean Med Sci; 2014 Jun; 29(6):811-7. PubMed ID: 24932083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal.
    Huang SC; Wu VC; Lin SY; Sheu WH; Song YM; Lin YH; Wu CC; Chang WD
    Thyroid; 2009 Jan; 19(1):13-20. PubMed ID: 19072673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
    Dinan MA; Li Y; Reed SD; Sosa JA
    Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of preparation method for radioactive iodine therapy on serum electrolytes.
    Takata N; Miyagawa M; Okada T; Kawaguchi N; Fujimoto Y; Kouchi Y; Tsuruoka S; Uwatsu K; Kido T
    Jpn J Radiol; 2023 Nov; 41(11):1247-1254. PubMed ID: 37184818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer : A Systematic Review and Meta-analysis.
    Park S; Bang JI; Kim K; Seo Y; Chong A; Hong CM; Lee DE; Choi M; Lee SW; Oh SW
    Clin Nucl Med; 2024 Mar; 49(3):e96-e104. PubMed ID: 38271262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.